- Conditions
- Glioblastoma, Gliosarcoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
- Interventions
- Biospecimen Collection, Magnetic Resonance Imaging, Navtemadlin, Radiation Therapy
- Procedure · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Los Angeles, California • Baltimore, Maryland + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–31
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Glioblastoma, Glioblastoma Multiforme
- Interventions
- Disulfiram, Copper gluconate, Temozolomide
- Drug · Dietary Supplement
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Glioblastoma (GBM)
- Interventions
- anti-EGFR bispecific-armed T cells, Low-Intensity Focused Ultrasound
- Drug · Device
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Glioblastoma
- Interventions
- Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics, CELLECTRA®2000 EP Device supplied by Geneos Therapeutics, Plasmid encoded IL-12
- Biological · Device · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Brain Cancer
- Interventions
- Nivolumab, Temozolomide, Radiotherapy
- Drug · Radiation
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 31 more
- Conditions
- Glioblastoma, IDH-wildtype
- Interventions
- Ropidoxuridine
- Drug
- Lead sponsor
- Shuttle Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Miami, Florida • Hackensack, New Jersey + 3 more
- Conditions
- Glioblastoma
- Interventions
- Cilengitide (2-times weekly), cilengitide (5-times weekly), Temozolomide, Radiotherapy
- Drug · Radiation
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Rockland, Massachusetts